Ignite Creation Date:
2024-05-06 @ 1:56 PM
Last Modification Date:
2024-10-26 @ 1:22 PM
Study NCT ID:
NCT04164238
Status:
UNKNOWN
Last Update Posted:
2019-11-15
First Post:
2019-11-11
Brief Title:
Neoadjuvant Anti-PD-1 Antibody Toripalimab or Combined With Chemotherapy in HNSCC Patients
Sponsor:
First Affiliated Hospital of Zhejiang University
Organization:
First Affiliated Hospital of Zhejiang University
Study Overview
Official Title:
Phase II Trial of Neoadjuvant Anti-PD-1 Antibody Toripalimab or Combined With Chemotherapy in Head and Neck Squamous Cell Carcinoma Patients
Status:
UNKNOWN
Status Verified Date:
2019-11
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study evaluate either Toripalimab or combined with chemotherapy as neoadjuvant treatment for patients with head and neck squamous cell carcinoma Participants in arm A receive Toripalimab in arm B receive Toripalimab plus PC paclitaxel and carboplatin arm C with Toripalimab plus modified TPFpaclitaxel and cisplatin and 5-fu
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None